凝血因子IX经鼻内给药的体内递送:一项概念验证研究
本研究在小鼠中评估重组凝血因子IX(rFIX)及rFIX-Fc融合蛋白经鼻内给药(IND)的递送效果。结果显示,rFIX与rFIX-Fc经鼻内给药后均能等效进入血液,主要经被动跨黏膜屏障转运,不依赖FcRn受体;FIX敲除小鼠经鼻给药后血浆FIX抗原与FIX活性均升高。该概念验证研究为鼻内途径作为FIX静脉输注替代方案治疗血友病B提供了证据支持。
要点
- rFIX与rFIX-Fc经鼻内给药后均能等效递送至血液,不依赖FcRn受体。
- 转运主要经被动跨黏膜屏障机制,与小鼠品系无关。
- FIX敲除小鼠经鼻给药后血浆FIX抗原与FIX活性水平均升高。
核心结论
- 该概念验证研究描述的证据支持鼻内途径作为FIX静脉输注的替代方案用于血友病B治疗。
研究设计与样本
- 研究将rFIX与rFIX-Fc液滴滴入野生型、FcRn敲除、FcRn人源化及FIX敲除小鼠鼻孔,评估rFIX黏膜摄取。
- 通过测定血浆FIX抗原与FIX活性(FIX:C)水平及鼻内给药后鼻黏膜组织学分析评估摄取。
主要发现
- 经鼻内给药后,rFIX与rFIX-Fc均等量递送至血液,与所研究小鼠品系无关。
- 转运主要经被动跨黏膜屏障机制,不依赖FcRn受体。
- FIX敲除小鼠经鼻内给药后血浆FIX抗原与FIX:C活性水平均升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hemophilia B (HB) is a bleeding disorder characterized by coagulation factor (F) IX (FIX) deficiency. The current standard-of-care for severe HB is prophylaxis with long-term repetitive intravenous (i.v.) infusions of recombinant FIX (rFIX) with standard half-life or extended half-life. Unmet needs remain regarding the development of non-invasive administration routes for coagulation factors. The aim of this study was to evaluate the effectiveness of intranasal delivery (IND) of rFIX and rFIX fused to Fc fragment (rFIX-Fc) in mice. METHODS: Drops of rFIX and rFIX-Fc were deposited in the nostrils of wild-type, FcRn knock-out, FcRn humanized, and FIX knock-out mice. rFIX mucosal uptake was evaluated by measuring plasma FIX antigen and FIX activity (FIX:C) levels, and by performing histologic analysis of the nasal mucosa following IND. RESULTS: After IND, both rFIX and rFIX-Fc were equally delivered to the blood compartment, irrespective of the mouse strain studied, mostly through a passive mechanism of transportation across the mucosal barrier, independent of FcRn receptor. Both plasma FIX antigen and FIX:C activity levels increased following IND in FIX knock-out mice. CONCLUSION: This proof-of-concept study describes evidence supporting the nasal route as an alternative to FIX i.v. infusion for the treatment of HB.
引用
- Fieux M, Rovera R, Coiffier C, et al. In vivo intranasal delivery of coagulation factor IX: a proof-of-concept study. J Thromb Haemost. 2023. PMID: 37633640. doi:10.1016/j.jtha.2023.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。